Metrics as of 10/15/2026, 11:41 PM (Berlin time), refresh in progress.
Cardiff Oncology Stock
Cardiff Oncology, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Mani Mohindru
- Employees
- 31
- Market cap
- $70 M
- IPO
- 27/07/2004
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses…
Cardiff Oncology stock: price history
1D
-7.2%
1W
-16.6%
1M
-33.3%
6M
-49.9%
YTD
-67.9%
1Y
-59.8%
2Y
-67.7%
5Y
-85.9%
10Y
-99.7%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~15% stronger price swings than usual
Ask the agents about Cardiff Oncology
Analyst assessment of Cardiff Oncology
PRICE TARGET LOW
US$2.00
CONSENSUS
US$2.00
MEDIAN
US$2.00
PRICE TARGET HIGH
US$2.00
0
STRONG BUY
8
BUY
6
HOLD
1
SELL
0
STRONG SELL
15
TOTAL · Buy
As of: 15/09/2026
Cardiff Oncology stock metrics
P/E
-1.62
P/B
2.5
EV/EBITDA
-1.72
RETURN ON EQUITY
-34.8%
NET MARGIN
-8,876.9%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.8%
FLOAT SHARES
72,995,470
AVG. DAILY VOLUME (30D)
715,746
Insider transactions (SEC)
Mohindru Mani
PACE GARY W
PACE GARY W
Mohindru Mani
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Cardiff Oncology stock
What does Cardiff Oncology do?
Cardiff Oncology, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Mani Mohindru, the company employs around 31 people.
The IPO was on 27/07/2004; the stock trades on NASDAQ under the ticker CRDF.
What do analysts say about Cardiff Oncology stock?
15 analysts rate the stock, the consensus is Buy (as of 15/09/2026).
The average price target is US$2.00, ranging from US$2.00 to US$2.00, with a median of US$2.00.
This is an external assessment, not a statement by Market Jury.
When does Cardiff Oncology report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 15% stronger than usual.
Does Cardiff Oncology pay a dividend?
No, Cardiff Oncology currently does not pay a dividend.
Which stocks are comparable to Cardiff Oncology?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Cardiff Oncology stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cardiff Oncology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.